AXLRx delivers evidence-led competitive, patient and payer intelligence — scoped to your asset, verified against a live source, and ready to put in front of a payer in 72 hours.
Launch and access timelines are compressing, driven by faster competitive disclosure and shorter payer response cycles, even as evidence requirements continue to rise. A commercial question that once tolerated a six-week engagement now needs an answer inside the same week it was asked — before the decision is made, not after.
Every brand decision sits in one of four commercial stages, each answering a single buyer question and scoped to your asset, not an off-the-shelf brief. The brief types live inside them.
"What does the competitive and scientific landscape look like?"
"How large is the opportunity and who controls access?"
"How do we position, segment and win share?"
"How do we measure performance and optimise the field?"
Every AXLRx brief is built around exhibits your team can act on, not paragraphs describing the category. Each one is scoped to your asset, and every figure carries the source it came from.
AXLRx uses none of its own memory as a source. Every figure is checked against the document it came from, then re-checked in an independent audit before delivery. If it cannot be traced to a source, it is removed, not estimated.
Every claim is cited to a live PMID, ClinicalTrials.gov ID or URL at the point of writing. Uncited claims are dropped, not estimated.
The figure must appear in the cited source, not merely be consistent with it. Metadata is fetched live, never recalled.
A separate pass re-checks every link, claim and number before delivery. One dropped figure is one too many.
AXLRx is a custom-built consulting engine, run by pharma practitioners, that answers the question in front of you, not a generic AI tool and not a syndicated PDF.
No hallucinated sources, no generic answers, no inconsistent output. Each brief type codifies the actual pharma commercial-intelligence process a launch or access team runs, not a generic prompt chain.
Cited to a live PMID, trial ID or URL at the point of writing. Defensible the moment you present it.
Scoped to your asset and proposed label, framing the decision — not describing the category in aggregate.
Adapted to the exact question, comparators and market in front of you. No two briefs are the same.
Methodology built on 20+ years of pharma commercial operations practice, and every recommendation reviewed by a pharma commercial consultant before it reaches you.
No seat licence, no dashboard to operate. The finished deliverable lands on your desk in 72 hours.
The difference between a good strategy and a winning one is not the strategy. It is the operational discipline around it.
Traditional consulting forces a choice: fast or thorough, affordable or rigorous. AXLRx delivers across all four on every engagement.
| AXLRx | Groundwork In-House | Syndicated Report | Generic AI Tool | |
|---|---|---|---|---|
| Time to brief | Days | 3–4 weeks of effort | Off-the-shelf, but fixed | Instant, but unreliable |
| Cost | ~90% lower | Weeks of senior analyst time | $10K–$50K per report | Free / low cost |
| Built to your question | Always, to your brief | Yes — built from scratch | Generic, pre-written | Generic — no pharma context |
| Hard-to-source markets | Any market, globally | Possible — slow to source | Major markets only | Hallucinated — cannot cite |
| Working formats | PDF, Excel, PowerPoint, Word | Yes — hand-built | PDF only | Chat text only |
200+ real cases and commercial playbooks built into the methodology
Consulting-grade intelligence on your timeline, not a retainer schedule.
Market entry, brand planning, and launch readiness, at the pace your commercial decisions require.
Competitive intelligence, patient sizing, and payer access, built before the deal closes. Deal speed, not engagement speed.
Accelerate the research and synthesis phase of any pharma commercial engagement, freeing your team for strategy and client delivery.
Pharma CI, market access and launch analysis.
Rare disease is the most attractive place in pharma to launch a drug, and one of the hardest to size. Both facts have the same cause: a small, hidden, genetic population. Which is why you do not measure a rare-disease market. You build one.
Read → commercial-planningA single rare-disease indication looks like one market and behaves like several. Genotype, organ, or antibody status splits the population into groups that cannot be added together. Sizing the indication as one number counts patients no single therapy can reach.
Read → commercial-planningWhen a rare disease enters a newborn-screening panel, it stops being a prevalent pool to penetrate and becomes an incident flow plus a depleting backlog. Market size becomes a function of screening coverage, a policy variable, not epidemiology.
Read →AXLRx is a pharma commercial-intelligence service by MoatRx. Each report is scoped to a single asset and delivered as a finished analyst report with an editable model and a slide readout.
Scope is confirmed within 24 hours and the finished report is delivered in 72 hours.
Every figure is cited to a live source — a PMID, ClinicalTrials.gov ID or primary URL — at the point of writing and re-checked in an independent audit pass. Uncited claims are dropped, not estimated.
AXLRx publishes Competitive Intelligence, Disease Landscape, Patient Flow Model, Payer & HTA, Field-Force Strategy, Launch Readiness, KOL Mapping, Pricing Strategy Model, Market Sizing Model and HTA Strategy Model reports, each mapped to a commercial stage.
Specify the indication, comparator set and market on the commission page; scope is confirmed in 24 hours and delivery follows in 72.
AXLRx codifies pharma commercial reasoning. AI-accelerated research, MoatRx's own consulting methodologies, and two decades of pharma commercial practice, applied to the question in front of you. Every figure is verified against a live source and reviewed by a practising consultant before it reaches you. It is the same discipline MoatRx brings to a full strategy engagement, compressed into a 72-hour brief.
About the team →Scope confirmed in 24 hours. Delivered in 72 hours. Every figure put in front of a payer.